Published by Iain Gilbert on 27th August 2026
(Sharecast News) - Drugmaker AstraZeneca said on Thursday that Tezspire had delivered positive Phase III results in eosinophilic oesophagitis (EoE), hitting both co‑primary endpoints and all key secondary measures, with improvements sustained through 52 weeks.
URL: http://www.digitallook.com/dl/news/story/36170770/...